Phase 3 Multiple Sclerosis Trial, Recruiting

Written by an AI model from the ISRCTN registry eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of multiple sclerosis (MS), specifically the Secondary Progressive (SPMS) or Primary Progressive (PPMS) type.
• People whose MS has been steadily getting worse over the past 2 years — as assessed by their treating doctor — rather than worsening due to relapses (flare-ups).
• People whose disability level, as measured by a standard MS scale (EDSS), falls between 4.0 and 8.0 at the time of joining the trial.
• People aged between 25 and 70 years old (inclusive) on the day they are assigned to a treatment group.
• People whose kidneys are working well enough, as shown by a blood test result meeting a specific threshold (confirm with trial site).
• People whose liver is functioning normally, based on blood test results for certain liver markers falling within acceptable ranges (confirm with trial site).
• People who are able and willing to follow the trial's treatment and appointment schedule, including being able to start treatment within 2 weeks of being assigned to a group.
• People who have given written consent to take part.

Who may not be able to join:

• People who have had an MS relapse (flare-up) within the 12 weeks before joining.
• People who have certain serious health conditions alongside their MS, including heart failure, significant breathing problems, kidney failure, cancer (unless fully in remission), uncontrolled thyroid disease, significant neurological conditions unrelated to MS, or liver problems.
• People with an active condition that seriously affects the body's ability to absorb food or nutrients (such as active coeliac disease).
• People with a history of alcohol use disorder or use of illicit drugs in the past 5 years (cannabis used for symptom relief is excluded from this).
• People who are pregnant or breastfeeding.
• Women who could become pregnant and are unwilling or unable to use an acceptable form of contraception during the trial and for 12 weeks after the last dose.
• Men whose partner could become pregnant and who are unwilling to use an acceptable form of contraception during the trial and for 12 weeks after the last dose.
• Men who are unwilling to stop donating sperm during the trial and for 12 weeks after the last dose.
• People who have taken part in another clinical trial involving an investigational medicine or device within the 26 weeks before joining.
• People who have been treated with steroids (by mouth or through a drip) for MS relapse or worsening within the 12 weeks before joining (steroids taken for a completely unrelated condition may be acceptable — confirm with trial site).
• People who have previously taken or are currently taking any of the medicines being studied in this trial within the 26 weeks before joining (a limited exception may apply for certain low-dose supplements — confirm with trial site).
• People who have started a new disease-modifying therapy or a medication called fampridine within the 26 weeks before joining.
• People taking certain other medicines that are not allowed to be combined with the trial treatments (confirm with trial site).
• People who are not suitable for any of the trial treatment options based on the specific rules for each treatment arm.
• People who have previously been treated with a medicine called alemtuzumab or have had a stem cell transplant using their own cells within the 52 weeks before joining.
• People whose urine test shows a protein-to-creatinine ratio at or above a certain level, indicating possible kidney stress (confirm with trial site).
• People who have a diagnosis of diabetes mellitus.

Important: Always verify eligibility with the trial site directly before applying.